Clinical Trial Exit Interview Study in Cutaneous T-cell Lymphoma (CTCL) to Capture Meaningful Treatment Benefit from a Patient's Perspective
Latest Information Update: 29 Apr 2021
At a glance
- Drugs Resiquimod (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Galderma Research & Development
- 29 Apr 2021 This Trial has been completed in Germany according to European Clinical Trials Database record.
- 09 Nov 2020 New trial record